Target
5-fluorouracil
40 abstracts
Abstract
FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.Org: Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik Dr. Hancken GmbH,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.Org: Florida Cancer Specialists North Division, Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), IPSEN Bioinnovation Limited, Università degli studi di Verona and Azienda Ospedaliera Universitaria Integrata,
Abstract
Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.Org: Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China, Sun Yat-sen Memorial Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors.Org: Global Medicines Development,
Abstract
Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial.Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,
Abstract
Neoadjuvant chemotherapy with FOLFOXIRI plus lateral lymph nodes dissection for the treatment of resectable rectal cancer with lateral lymph node metastasis: A single-arm, investigator-initiated, phase II trial.Org: State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, Comprehensive Third Ward, Cancer Institute & Hospital,
Abstract
Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.Org: Atrium Health Wake Forest University Baptist Medical Center,
Abstract
BreAK CRC, a first-in-human phase I/II trial of STC-1010, a new allogenic cancer vaccine for advanced or metastatic unresectable colorectal cancer.Org: Centre Hospitalier Universitaire de Poitiers, Poitiers, France, Department of Clinical Research, Centre Léon Bérard, Lyon, France, 4 rue Eric de Cromières, Clermont-Ferrand, France, Brenus Pharma, Clermont-Ferrand, France, Medical Oncology Department, Centre Georges-François Leclerc, University of Bourgogne Franche-Comté, Dijon, France,
Abstract
Efficacy of oncolytic virus combined with HAIC of mFOLFOX for IMCC: A single-center, single-arm, prospective study.Org: Hepatobiliary Pancreatic Center Department,
Abstract
A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.Org: Liaoning Cancer Hospital, Shenyang, China, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Yunnan Cancer Hospital, Yunnan, China, CSPC Ouyi Pharmaceutical Technology (Shijiazhuang) Co.,Ltd, Shijiazhuang, China,
Abstract
Updated results from venous infusion chemotherapy (VIC) plus apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.Org: Department of Hepatobiliary Surgery,
Abstract
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.Org: Gradyate School of Medicine, Department of Radiation Oncology and Image-Applied Therapy, Department of Therepeutic Oncology, Department of Clinical Trial Promotion, Clinical Trial Promotion Department,
Abstract
Modifying the gastric tumor microenvironment with tadalafil: A transcriptomic analysis of immune signatures from underserved patients of southern Arizona.Org: The University of Arizona Cancer Center, University of Arizona Cancer Center, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
The treatment outcomes of patients with BRAFV600E–mutated metastatic colorectal cancer (mCRC): The Polish retrospective cohort study.Org: Institute of Medical Science, University of Opole, Military Clinical Hospital with Polyclinic, Department of Clinical Biochemistry and Laboratory Diagnostics,
Abstract
A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus.Org: Department II of Interventional Radiology,
Abstract
FOLFOX-based hepatic arterial infusion chemotherapy combined with regorafenib for unresectable colorectal liver metastases.Org: Hubei Province Key Laboratory of Molecular Imaging,
Abstract
Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis.Org: the Naval Medical University,
Abstract
Dermatology-related quality of life outcomes in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: A prespecified secondary analysis of the phase 2 randomized PanaMa (AIO KRK 0212) trial.Org: Gesundheitszentrum St Marien, Amberg, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, Charité-University madicine Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, Germany, Practice of Hematology and Oncology (HOPE), Hamburg, Germany, Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany,
Abstract
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma.Org: Cancer Research Center of Marseille (CRCM), Digestive and Medical Oncology Department, Paul Brousse Hospital, Cancer Centre of Southeastern Ontario/Queen's University, Paoli-Calmettes Institute,
Abstract
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.Org: Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera Universitaria Integrata di Verona, Hospital Universitario Miguel Servet, Centre Léon Bérard, Masaryk Memorial Cancer Institute,
Abstract
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,
Abstract
Size-related heterogeneity of colorectal liver metastases (CRLM) in patients with advanced RAS wild-type metastatic colorectal cancer (mCRC) treated in the PanaMa trial: Implication for treatment decisions.Org: Department of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Charité– Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Berlin, Germany, Charité– Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet Zu Berlin, Berlin, Germany, Klinikum Neuperlach/ Klinikum Harlaching, Department of Hematology, Oncology, and Palliative Care, Munich, Germany, Klinik Dr. Hancken GmbH, Department of Hematology, Oncology, and Palliative Care, Stade, Germany, Kliniken Maria Hilf GmbH, Moenchen-Gladbach, Germany, Oncological Practice UnterEms, Leer, Germany, University Medical Center Goettingen, Department of Gastroenterology, Gastrointestinal Oncology, and Endocrinology, Goettingen, Ge...,
Abstract
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,
Abstract
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.Org: Yonsei Cancer Center, Yonsei University Health System, Maria Sklodowska-Curie National Research Institute of Oncology, James Lind Cancer Research Center, Temuco, Chile, Harbin Medical University Cancer Hospital, Asan Medical Center,
Abstract
Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and personalized chemotherapy in PDAC.Org: Cancer Research Center of Marseille (CRCM), Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, CNRS UMR 5309-INSERM U1209, Institut Paoli-Calmettes, Marseille, France, Aix-Marseille University CHU Timone,
Abstract
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.Org: University of Florida/UF Health Cancer Center, University of Florida Health Cancer Center, Orlando Health Cancer Institute, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,
Abstract
Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.Org: Jina Pharmaceuticals, Intas Pharmaceuticals Ltd.,
Abstract
Impact of number and size of colorectal metastases (CRM) on survival in patients with RAS wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212).Org: Department of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Charité– Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Berlin, Germany, Charité– Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet Zu Berlin, Berlin, Germany, Klinikum Neuperlach/ Klinikum Harlaching, Department of Hematology, Oncology, and Palliative Care, Munich, Germany, Klinik Dr. Hancken GmbH, Department of Hematology, Oncology, an...,
Abstract
The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC)—ISRCTN83842641.Org: University of Leeds, University of Glasgow, University of Birmingham, Patient representative, Christie NHS Foundation Trust, Manchester, United Kingdom,
Abstract
Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Center GF Leclerc, Georges-François Leclerc Cancer Center, Georges François Leclerc Cancer Center – UNICANCER, Dijon, France, William Morey Hospital,
Abstract
A pragmatic, single-arm clinical trial of a dose-adjustment algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy.Org: Dartmouth Cancer Center, Lebanon, NH, Dartmouth Cancer Center, Nashua, NH, Dartmouth Cancer Center, St. Johnsbury, VT,
Abstract
Efficacy and safety of induction chemotherapy with docetaxel + cisplatin in selected groups of patients with HNSCC.Org: Pavlov University, Saint-Petersburg, Russian Federation, Saint-Petersburg State University, Medical Faculty Mannheim, SPb SBIH City clinical oncology dispensary,
Abstract
Real-world treatment patterns and total cost of care in Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX.Org: Milliman, Inc., Ipsen Biopharmaceuticals, Inc., George Washington University Hospital,
Abstract
A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.Org: Virginia Cancer Specialists, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan,
Abstract
The smart options of induction therapy for locally advanced betel-nuts related HNSCC in Taiwan.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan Bio Therapeutics, Yun-lin Branch,
Abstract
Oxaliplatin based chemotherapy for advanced well-differentiated neuroendocrine tumors: A systematic review and meta-analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Jinan, China National Biotec Group,
Abstract
Survival outcomes of liposomal irinotecan in patients with advanced pancreatic adenocarcinoma previously treated with conventional irinotecan-based chemotherapy: A single-institution experience.Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Baltimore, MD,
Abstract
Clinical outcomes of extramammary Paget’s disease in Korea: A multicenter, retrospective study.Org: Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea, Asan Medical Center, Seoul National University Hospital, Samsung Medical Center, Seoul St. Mary's Hospital,
Abstract
The prognostic impact of NKA dynamics in first-line treatment of metastatic colorectal cancer.Org: Department of Biochemistry & Immunology, Danish Colorectal Cancer Center South, Institute of Regional Health Research, University Hospital of Southern Denmark, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,